ClinicalTrials.gg
Active, not recruitingNCT02896452PCOSUpdated Nov 12, 2026

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

An observational study in Polycystic Ovarian Syndrome and Idiopathic Intracranial Hypertension, sponsored by National Aeronautics and Space Administration (NASA). Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Aeronautics and Space Administration (NASA) · Observational

How we know

Updated Nov 12, 2026Study completion movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Enrollment
19th of 35
60 · median 65
Started
2016
with 7 others
Observational
37 of 183
8 open now
Primary completion
2020-03
later than 0 of 41 live
Registered
115th of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 19th largest by enrollment of the 35 observational ones that give a count, is one of 8 that started in 2016, is one of 37 observational ones, reaches primary completion later than 0 of the 41 other live ones, and was the 115th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The investigators have documented a genetic predisposition for some astronauts to develop ophthalmologic issues (e.g., choroidal folds, cotton wool spots, optic disc edema). Women with polycystic ovary syndrome (PCOS) have several characteristics similar to those described in astronauts, including: higher homocysteine concentrations, increased incidence of intracranial hypertension, increased retinal nerve fiber layer thickness, increased incidence of white matter hyperintensities on MRI, increased androgen concentrations (or androgen responses to space flight), and indices of altered carbohydrate metabolism. Women with PCOS have not been evaluated in detail regarding the occurrence of other anomalies observed in astronauts including choroidal folds, optic disc edema and cotton wool spots as well as changes in cycloplegic refraction, and optic nerve sheath diameter. While researchers have evaluated one-carbon metabolism pathway polymorphisms re: PCOS, and initial studies show an association with certain one-carbon polymorphisms, none have looked at the complete set of SNPs proposed here. This study will evaluate women with PCOS and/or idiopathic intracranial hypertension (IIH) to assess one-carbon biochemistry and genetics and their possible correlation with ophthalmologic findings. The investigators aim to clarify the relationship of one carbon metabolism and ophthalmic findings in astronauts and patients with PCOS and/or IIH.

Read the detailed description

Evidence from initial analysis of 5 SNPs in the one-carbon metabolism pathway suggests that one-carbon pathway genes may predict risk of ocular changes and possible vision impairment during and after long-duration space flight. It is not precisely known whether it is these particular genes, or a haplotype of genes that are linked to these genes, that influence risk. Furthermore, ancestry is a strong factor that predicts SNP occurrence in a population, and the association between one-carbon metabolism and the risk of vision-related issues may simply stem from the fact that one particular ancestry has a higher prevalence of these SNPs.

The investigators propose that there are other SNPs in the one-carbon metabolism pathway that alter risk of ocular changes and potential vision impairment during long-duration spaceflight. To that end, extended studies of one-carbon genetics in astronauts have recently been initiated. The investigators hypothesize that the differences between genetic, biochemical, and ophthalmologic findings in PCOS and/or IIH patients and controls will mirror many of the differences found between astronauts who had ophthalmic issues during and after flight.

SPECIFIC AIMS

The key aims of this study are to: a) determine extensive one carbon pathway and related biochemistry, targeted metabolomics, and genetics (523 SNPs of the 85 major genes), and b) conduct ophthalmologic exams on patients in one of four treatment groups:

  1. women diagnosed with PCOS without IIH
  2. women diagnosed with PCOS and IIH
  3. women diagnosed with IIH without PCOS
  4. women without PCOS or IIH Participants will be matched by age and body mass index (BMI). Statistical analyses will be used to evaluate the independent and shared contributions of age, body mass (BMI), and genetics on biochemical, and ophthalmologic outcomes, with False Discovery Rate adjustments to account for multiple comparisons.

A secondary aim is to combine the patient and control data from this study with ISS crewmember data in order to help inform us on whether or not these two cohorts (astronauts with ophthalmic issues, PCOS patients) share similar associations among one-carbon metabolism genetics and biochemistry and ophthalmologic data identified in the investigators' earlier analyses.

03

Conditions studied

  • Polycystic Ovarian Syndrome
  • Idiopathic Intracranial Hypertension
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Premenopausal women, age 18-50 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PCOS and/or IIH
  • No current medications for the treatment of PCOS
  • Age and -matched healthy women without PCOS or IIH will be used as controls

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of Cushing's syndrome
  • Untreated hypo/hyperthyroidism, elevated prolactin, congenital adrenal hyperplasia, renal insufficiency or diabetes.
  • Currently taking medications that can affect androgen concentrations or insulin sensitivity.
  • Pregnant, breast-feeding, taking oral or currently smoking.
  • Taking medications that affect folate or B12 metabolism, such as methotrexate, trimethoprim, triamterene, phenobarbital, phenytoin, carbamazepine, gabapentin, or primidone or topiramate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Women diagnosed with PCOS without IIH

    Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension

  • Women diagnosed with PCOS and IIH

    Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension

  • Women diagnosed with IIH without PCOS

    Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome

  • Women without PCOS or IIH

    Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension

06

What researchers measure

Primary outcomes

  1. Single Nucleotide Polymorphism (SNP) Genetic Testing related to 1-Carbon Metabolism Pathway for 523 SNPs

    Time frame: 1 Day

  2. Ophthalmologic exam -OCT

    Optical coherence tomography test

    Time frame: 1 Day

  3. Ophthalmologic exam -Fundus

    Fundus photography

    Time frame: 1 Day

  4. Ophthalmologic exam - US

    Eye ultrasound exam

    Time frame: 1 Day

  5. Ophthalmologic exam -Vision

    Cycloplegic refraction test

    Time frame: 1 Day

  6. Ophthalmologic exam -IOP

    Intraocular pressure

    Time frame: 1 Day

Secondary outcomes

  1. Questionnaire

    Questions related to birthplace, as well as birthplace of parents and grandparents, if known

    Time frame: 1 Day

  2. B-vitamin Status - folate

    Serum Folate measurement

    Time frame: 1 Day

  3. B-vitamin Status - B12

    Methylmalonic acid

    Time frame: 1 Day

  4. B-vitamin Status - serum B12

    Serum vitamin B-12

    Time frame: 1 Day

  5. Testosterone

    Time frame: 1 Day

  6. Hemoglobin

    Time frame: 1 Day

  7. Plasminogen Activator Inhibitor Antigen

    Time frame: 1 Day

  8. Insulin

    Time frame: 1 Day

  9. Homocysteine

    Time frame: 1 Day

07

Study locations

1 site
08

References and documents

Publications

  • Zwart SR, Gregory JF, Zeisel SH, Gibson CR, Mader TH, Kinchen JM, Ueland PM, Ploutz-Snyder R, Heer MA, Smith SM. Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes. FASEB J. 2016 Jan;30(1):141-8. doi: 10.1096/fj.15-278457. Epub 2015 Aug 27. PubMed 26316272 ↗
  • Zwart SR, Gibson CR, Mader TH, Ericson K, Ploutz-Snyder R, Heer M, Smith SM. Vision changes after spaceflight are related to alterations in folate- and vitamin B-12-dependent one-carbon metabolism. J Nutr. 2012 Mar;142(3):427-31. doi: 10.3945/jn.111.154245. Epub 2012 Feb 1. PubMed 22298570 ↗

Individual participant data

Plan to share: Yes — Data will be provided upon subject request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Mar 2020, 41 months.

Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's 41 months is above that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Sep 2028, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2016
First posted
Sep 12, 2016
StartActual
Oct 1, 2016
Primary completionActual
Mar 2020
CompletionEst.
Sep 2028was Sep 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 2026→Sep 2028
Nov 12, 2026
Sponsor
National Aeronautics and Space Administration→National Aeronautics and Space Administration (NASA)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Study completion Sep 2026→Sep 2028
    Sponsor National Aeronautics and Space Administration→National Aeronautics and Space Administration (NASA)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02896452
Lead sponsor
National Aeronautics and Space Administration (NASA)
Collaborators
University of Texas, Mayo Clinic, University of Florida, University of North Carolina, Coastal Eye Associates
Responsible party
Scott M. Smith (Nutritionist, Manager for Nutritional Biochemistry, National Aeronautics and Space Administration (NASA)) — Principal investigator
First posted
Sep 12, 2016
Start date
Oct 1, 2016
Primary completion
Mar 2020
Completion
Sep 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Scott M Smith, PhD
principal investigator · National Aeronautics and Space Administration (NASA)
Alice Y Chang, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion